Resource Filter: Product
Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment
Date
Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer
Date
The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors
Date
Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules
Date
A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides
Date
Antibody and panel validation to advance spatial biology research
Date
Fully Automated Sequential Immunofluorescence (seqIF) for Hyperplex Spatial Proteomics
Date
Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas
Date
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Date
Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma
Date